Suppliers and packagers for TYGACIL

TYGACIL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-4990-20	10 VIAL, SINGLE-DOSE in 1 CARTON (0008-4990-20) / 5 mL in 1 VIAL, SINGLE-DOSE (0008-4990-19)	2008-06-15
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821	NDA	Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.	0008-4994-20	10 VIAL, SINGLE-DOSE in 1 CARTON (0008-4994-20) / 5 mL in 1 VIAL, SINGLE-DOSE (0008-4994-19)	2017-02-08

Tygacil (Tigecycline) Supplier Landscape

Last updated: February 19, 2026

This report analyzes the critical supplier landscape for Tygacil (tigecycline), a broad-spectrum glycylcycline antibiotic. Understanding the supply chain for active pharmaceutical ingredients (APIs) and key intermediates is essential for ensuring manufacturing continuity, managing costs, and mitigating risks for pharmaceutical companies and investors.

Who are the Primary API Manufacturers for Tigecycline?

The primary manufacturers of tigecycline API are predominantly located in Asia, specifically China and India, which are global hubs for pharmaceutical ingredient production. These entities possess the chemical synthesis capabilities and regulatory compliance necessary for large-scale API manufacturing.

• China: Several Chinese chemical and pharmaceutical companies are established suppliers or potential manufacturers of tigecycline API. These firms often benefit from economies of scale and integrated supply chains for raw materials.
• India: Indian pharmaceutical manufacturers, known for their expertise in generic API production and strong regulatory track records with agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are also significant players.

Specific company names involved in API manufacturing are often proprietary or subject to change due to market dynamics, regulatory approvals, and contract manufacturing agreements. However, the general trend indicates a concentration of manufacturing capacity in these two regions.

What are the Key Intermediates Required for Tigecycline Synthesis?

The synthesis of tigecycline is a complex, multi-step chemical process involving several key intermediates. The reliable sourcing of these precursors is as critical as the API manufacturing itself.

The general synthetic route for tigecycline involves modifications of minocycline, a tetracycline derivative. Key structural components and precursors include:

• Minocycline: This is a foundational molecule, often sourced as an intermediate itself or synthesized from earlier precursors.
• Glycylamide Moiety: The introduction of the N,N-dimethylglycylamide side chain is a defining step in tigecycline synthesis. Precursors for this moiety are critical.
• Specific Reagents: Various specialized reagents are required for functional group transformations, protection/deprotection steps, and coupling reactions. These can include specific amines, acylating agents, and catalysts.

The exact chemical intermediates and their suppliers are often trade secrets or dependent on the specific patented synthesis routes employed by API manufacturers. However, companies specializing in complex organic synthesis and fine chemicals are likely to be involved in supplying these upstream components.

What Regulatory Considerations Impact Tigecycline Supply?

The supply of tigecycline API and its intermediates is subject to stringent regulatory oversight to ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All API manufacturers must adhere to current GMP standards as defined by regulatory bodies such as the FDA, EMA, and the World Health Organization (WHO). This includes robust quality management systems, validated processes, and detailed documentation.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies referencing these DMFs in their drug applications rely on their completeness and regulatory acceptance.
• Inspections and Audits: Manufacturing facilities are subject to regular inspections by regulatory authorities and audits by their pharmaceutical clients. Successful audits are a prerequisite for market access and continued supply.
• Impurity Profiling and Control: Regulatory agencies require rigorous control and characterization of impurities in the API. Suppliers must demonstrate their ability to consistently produce tigecycline API with impurity levels below established thresholds.
• Supply Chain Traceability: Increasingly, regulators are emphasizing end-to-end supply chain traceability to prevent counterfeiting and ensure the integrity of the pharmaceutical supply.

How Does Patent Exclusivity Affect Tigecycline Sourcing?

The patent landscape significantly influences the sourcing of tigecycline. Patents can cover the compound itself, its synthesis methods, polymorphs, and specific formulations.

• Composition of Matter Patents: The initial patent on tigecycline (e.g., by Wyeth, now Pfizer) granted market exclusivity for a defined period. Once these primary patents expire, generic manufacturers can enter the market, potentially increasing competition among API suppliers.
• Process Patents: Even after composition of matter patents expire, secondary patents covering novel or improved synthesis routes can still restrict certain manufacturing methods. Generic manufacturers must develop or license non-infringing processes.
• Exclusivity Periods: The duration of patent exclusivity, including any extensions (e.g., Hatch-Waxman Act extensions in the US), dictates when generic competition can arise. For tigecycline, key composition of matter patents have expired or are nearing expiration in major markets, paving the way for generic development and supply diversification.
• Freedom to Operate (FTO): Companies looking to manufacture or source tigecycline API must conduct thorough FTO analyses to ensure their chosen synthesis route and sourcing strategy do not infringe on existing patents.

What Are the Potential Risks in the Tigecycline Supply Chain?

Disruptions in the supply chain for critical medicines like tigecycline can have significant consequences for patient access and company revenue. Key risks include:

• Geopolitical Instability: Concentration of manufacturing in specific regions (e.g., China, India) exposes the supply chain to risks associated with trade disputes, political tensions, or regional conflicts.
• Regulatory Changes: Unexpected changes in regulatory requirements in manufacturing countries or key import markets can lead to production halts or increased compliance costs.
• Quality Control Failures: Any lapse in quality control by an API manufacturer can result in product recalls, regulatory sanctions, and damage to reputation, impacting the entire supply chain.
• Natural Disasters and Pandemics: Events such as earthquakes, floods, or global health crises (like COVID-19) can disrupt production, logistics, and raw material availability.
• Supplier Solvency: The financial stability of key API or intermediate suppliers is a critical factor. The bankruptcy or withdrawal of a major supplier can create significant shortages.
• Intellectual Property Disputes: Ongoing patent litigation or newly filed patents can create uncertainty and potentially disrupt established supply relationships.

How Does Cost Structure Influence Tigecycline Sourcing Decisions?

Cost is a primary driver in sourcing decisions for pharmaceutical ingredients, balanced against quality and reliability.

• Raw Material Costs: The price and availability of upstream chemicals required for tigecycline synthesis directly impact the final API cost.
• Manufacturing Overhead: Labor, energy, waste disposal, and capital depreciation at manufacturing sites contribute significantly to API production costs. Asian manufacturers often have cost advantages in these areas.
• Regulatory Compliance Costs: Investments in GMP facilities, quality systems, and regulatory submissions (e.g., DMF fees, inspection costs) add to the overall cost of goods.
• Transportation and Logistics: Shipping costs, import duties, and the complexities of international logistics add to the landed cost of the API.
• Economies of Scale: Larger production volumes generally lead to lower per-unit costs for API manufacturers.

The entry of generic competition following patent expirations typically drives down the price of tigecycline API as multiple suppliers compete for market share.

Who are the Key Players in the Tigecycline Market?

The tigecycline market includes the originator company, generic manufacturers, and API suppliers.

• Originator: Pfizer (following its acquisition of Wyeth) remains a key player with its branded Tygacil product.
• Generic Manufacturers: As patents have expired, numerous generic pharmaceutical companies are developing and marketing tigecycline products. These companies are crucial customers for API suppliers.
• API Manufacturers: These are the companies that synthesize and supply the bulk tigecycline API to finished dosage form manufacturers. This category is critical for understanding supply chain dynamics.
• Intermediate Suppliers: Companies that produce the chemical building blocks used in tigecycline synthesis.

The competitive landscape among API suppliers is influenced by their manufacturing capacity, regulatory approvals, pricing, and established relationships with generic drug makers.

What are the Future Trends in Tigecycline Supply?

Several trends are likely to shape the future supply of tigecycline.

• Increased Generic Competition: With patent expirations, the market is likely to see a proliferation of generic tigecycline products, leading to greater demand for API from multiple suppliers.
• Supply Chain Diversification: Pharmaceutical companies may seek to diversify their API sourcing beyond a single supplier or region to mitigate risk, potentially opening opportunities for new manufacturers.
• Focus on Supply Chain Resilience: Geopolitical and public health events have highlighted the need for robust and resilient supply chains, leading to increased scrutiny of supplier locations and contingency planning.
• Advancements in Synthesis Technologies: Ongoing research into more efficient, cost-effective, or environmentally friendly synthesis routes could alter the competitive landscape among API manufacturers.
• Regulatory Harmonization and Stringency: Continued efforts toward global regulatory harmonization, alongside increasing stringency in quality and data integrity expectations, will shape the requirements for API suppliers.

Key Takeaways

• Tigecycline API manufacturing is primarily concentrated in China and India, with these regions offering significant cost advantages and established chemical synthesis expertise.
• The synthesis requires a complex chain of intermediates, the reliable sourcing of which is crucial for uninterrupted API production.
• Stringent regulatory requirements, including GMP compliance and successful DMF filings, are mandatory for API suppliers and significantly influence market access.
• The expiration of key composition of matter patents has opened the door for generic competition, increasing demand for API and driving price pressures.
• Supply chain risks include geopolitical factors, regulatory shifts, quality control failures, and disruptions from natural disasters or pandemics.
• Cost remains a critical factor, influenced by raw material prices, manufacturing overhead, and economies of scale, with Asian suppliers often holding a competitive edge.
• Future trends point towards increased generic competition, a drive for supply chain diversification and resilience, and continuous evolution of synthesis technologies and regulatory standards.

Frequently Asked Questions

1. What is the typical lead time for sourcing tigecycline API from Asian manufacturers? Lead times can vary significantly, typically ranging from 3 to 9 months, depending on supplier capacity, existing orders, and the complexity of the required specifications. Advance planning and strong supplier relationships are crucial.
2. Are there any non-Asian countries with significant tigecycline API manufacturing capacity? While the vast majority of large-scale API production for tigecycline is based in China and India due to cost efficiencies and established infrastructure, some specialized chemical manufacturers in Europe and North America may produce intermediates or offer custom synthesis for specific niche requirements, though not typically for bulk commercial API supply.
3. What are the primary quality metrics that buyers of tigecycline API scrutinize? Buyers meticulously examine purity (typically >98%), impurity profiles (specific and unspecified impurities must be within pharmacopeial limits or agreed specifications), residual solvents, water content, physical characteristics (e.g., particle size distribution), and microbiological limits.
4. How can a pharmaceutical company verify the regulatory compliance of a potential tigecycline API supplier? Verification involves reviewing the supplier's FDA/EMA DMF, requesting recent inspection reports, conducting on-site audits of their manufacturing facilities, and verifying their Quality Management System documentation. Third-party quality assurance services can also be engaged.
5. What impact do different polymorphic forms of tigecycline have on its supply and manufacturing? Polymorphism can affect the API's physical properties, such as solubility and stability, which in turn influence formulation development and bioavailability. Manufacturers must control and consistently produce the desired polymorph, and this requires validated manufacturing processes and analytical methods. Suppliers must provide assurance of polymorph control.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidances-drugs/drug-master-files [2] European Medicines Agency. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/manufacturing/good-manufacturing-practice [3] World Health Organization. (n.d.). Good manufacturing practices for pharmaceutical products. Retrieved from https://www.who.int/teams/health-products-policy-and-standards/standards-and-specifications/good-manufacturing-practices [4] U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act. Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cders-office-generics/hatch-waxman-act